Covered recipient · General Payments record
RYAN W JACOBS
Allopathic & Osteopathic Physicians Internal Medicine Hematology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$184,315.71
194 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $127,251.25 | 61 |
| Consulting Fee | $44,423.33 | 19 |
| Travel and Lodging | $8,255.86 | 34 |
| Food and Beverage | $4,385.27 | 80 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Pharmacyclics LLC, An AbbVie Company | $44,231.40 | 57 |
| Janssen Biotech, Inc. | $40,409.77 | 48 |
| Secura Bio, Inc. | $33,937.46 | 21 |
| AstraZeneca Pharmaceuticals LP | $32,297.50 | 30 |
| BeiGene USA, Inc. | $11,641.44 | 10 |
| AbbVie Inc. | $8,439.13 | 6 |
| TG THERAPEUTICS, INC. | $6,194.34 | 11 |
| Adaptive Biotechnologies Corporation | $2,895.97 | 4 |
| Genentech USA, Inc. | $2,250.37 | 5 |
| Janssen Scientific Affairs, LLC | $1,010.00 | 1 |
| BeiGene, Ltd. | $1,008.33 | 1 |
Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RYAN W JACOBS
NPI 1114160082 · CMS profile ID 423472
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology
CHARLOTTE, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1114160082?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RYAN W JACOBS, NPI 1114160082, CMS profile ID 423472. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1114160082?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). RYAN W JACOBS, NPI 1114160082, CMS profile ID 423472. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1114160082?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- RYAN W JACOBS, NPI 1114160082, CMS profile ID 423472, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1114160082?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
194 matching records · $184,315.71 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 194.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Pharmacyclics LLC, An AbbVie Company | $25.00 | 08/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006833 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $29.22 | 08/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006835 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $34.50 | 08/05/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006837 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $64.00 | 08/05/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006839 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $65.00 | 08/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006841 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $101.26 | 08/05/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006843 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $229.00 | 08/05/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006845 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $347.66 | 08/05/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006847 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $716.84 | 08/05/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006849 | CMS |
| Janssen Biotech, Inc. | $4,100.00 | 08/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823631 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $4,100.00 | 08/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006809 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $4,100.00 | 08/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006811 | CMS |
| Secura Bio, Inc. | $6,270.00 | 08/03/2021 | Consulting Fee | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 851659931 | CMS |
| BeiGene USA, Inc. | $650.00 | 08/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846700789 | CMS |
| Janssen Biotech, Inc. | $16.00 | 07/30/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823495 | CMS |
| Janssen Biotech, Inc. | $15.30 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823507 | CMS |
| Janssen Biotech, Inc. | $5.33 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823519 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $111.74 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006807 | CMS |
| Janssen Biotech, Inc. | $125.00 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823457 | CMS |
| Janssen Biotech, Inc. | $396.46 | 07/29/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823465 | CMS |
| Janssen Biotech, Inc. | $35.00 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823475 | CMS |
| Janssen Biotech, Inc. | $7.50 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823487 | CMS |
| Janssen Biotech, Inc. | $303.96 | 07/28/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823603 | CMS |
| Janssen Biotech, Inc. | $25.00 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823609 | CMS |
| Janssen Biotech, Inc. | $8.01 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823627 | CMS |
| Janssen Biotech, Inc. | $115.35 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823549 | CMS |
| Janssen Biotech, Inc. | $252.48 | 07/27/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823561 | CMS |
| Janssen Biotech, Inc. | $22.78 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823570 | CMS |
| Janssen Biotech, Inc. | $12.00 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823581 | CMS |
| Janssen Biotech, Inc. | $7.33 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823591 | CMS |
| Janssen Biotech, Inc. | $1,500.00 | 07/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823743 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $22.01 | 07/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006803 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $1,500.00 | 07/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006805 | CMS |
| Adaptive Biotechnologies Corporation | $1,050.00 | 07/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844349107 | CMS |
| BeiGene USA, Inc. | $85.72 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846700791 | CMS |
| Janssen Biotech, Inc. | $1,500.00 | 07/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787823537 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $62.46 | 07/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006799 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $1,500.00 | 07/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006801 | CMS |
| AstraZeneca Pharmaceuticals LP | $300.00 | 06/24/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830089443 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $1,500.00 | 06/23/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006797 | CMS |
| Secura Bio, Inc. | $8.69 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 851659927 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,450.00 | 06/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829845813 | CMS |
| AstraZeneca Pharmaceuticals LP | $213.79 | 06/15/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829388353 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829428317 | CMS |
| AstraZeneca Pharmaceuticals LP | $179.37 | 06/15/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829640963 | CMS |
| AstraZeneca Pharmaceuticals LP | $665.70 | 06/15/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829903259 | CMS |
| AstraZeneca Pharmaceuticals LP | $103.03 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830256359 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,100.00 | 06/14/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829962561 | CMS |
| Secura Bio, Inc. | $56.24 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 851659923 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $1,500.00 | 06/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781006795 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $240.00 | 1 |
| PY2025 | Principal investigator | $2,655,472.64 | 116 |
| PY2024 | Recipient | $2,008.18 | 2 |
| PY2024 | Principal investigator | $2,323,263.29 | 33 |
| PY2023 | Principal investigator | $1,527,517.76 | 22 |
| PY2022 | Principal investigator | $192,595.11 | 14 |
| PY2021 | Principal investigator | $154,290.11 | 17 |
| PY2020 | Principal investigator | $89,713.40 | 4 |
| PY2019 | Principal investigator | $43,287.92 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
117 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $550.00 | 12/31/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH UNION | A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies | No dispute reported | 06/30/2026 | 1202404392 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,080.00 | 12/23/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190340529 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $12,117.00 | 12/09/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190329951 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $33,150.00 | 12/09/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190335760 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,219.89 | 12/04/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184268999 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,395.20 | 12/03/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342615 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,366.89 | 12/03/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342619 |
| Principal investigator 1 | BeOne Medicines Ltd. | $546.84 | 12/03/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342623 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,395.20 | 12/03/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342630 |
| Principal investigator 1 | BeOne Medicines Ltd. | $10,934.28 | 12/03/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342634 |
| Principal investigator 1 | BeOne Medicines Ltd. | $546.84 | 12/03/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342637 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,366.89 | 12/03/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342642 |
| Principal investigator 1 | BeOne Medicines Ltd. | $10,934.28 | 12/03/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342646 |
| Principal investigator 1 | BeOne Medicines Ltd. | $50,304.00 | 12/02/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190344303 |
| Principal investigator 1 | BeOne Medicines Ltd. | $736.00 | 11/25/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190340538 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,667.82 | 11/25/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184264435 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,345.54 | 11/14/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184261203 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,660.00 | 11/12/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190340534 |
| Principal investigator 1 | BeOne Medicines Ltd. | $182.28 | 11/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342548 |
| Principal investigator 1 | BeOne Medicines Ltd. | $182.28 | 11/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342551 |
| Principal investigator 1 | BeOne Medicines Ltd. | $455.63 | 11/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342555 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,697.60 | 11/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342558 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,697.60 | 11/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342562 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,644.76 | 11/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342564 |
| Principal investigator 1 | BeOne Medicines Ltd. | $455.63 | 11/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342566 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,758.08 | 11/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342570 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,758.08 | 11/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342574 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,644.76 | 11/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190342578 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $197.25 | 11/10/2025 | Non-covered Recipient Entity LEVINE CANCER INST | A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) | No dispute reported | 06/30/2026 | 1185554604 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,245.10 | 11/07/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184258259 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,345.54 | 10/29/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184253602 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $8,623.00 | 10/28/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190329949 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,322.01 | 10/23/2025 | Covered Recipient Teaching Hospital Atrium Health Cabarrus | A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) | No dispute reported | 06/30/2026 | 1185554606 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,345.54 | 10/23/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184252528 |
| Principal investigator 1 | ABBVIE INC. | $83,934.81 | 10/16/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies | No dispute reported | 06/30/2026 | 1202404338 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,189.61 | 10/16/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184250547 |
| Principal investigator 1 | BeOne Medicines Ltd. | $78,600.00 | 10/13/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330373 |
| Principal investigator 1 | BeOne Medicines Ltd. | $100,608.00 | 10/13/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190330447 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,069.18 | 10/03/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184244591 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,644.76 | 09/25/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190344337 |
| Principal investigator 1 | BeOne Medicines Ltd. | $182.28 | 09/25/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190344342 |
| Principal investigator 1 | BeOne Medicines Ltd. | $455.63 | 09/25/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 1190344346 |
| Principal investigator 1 | BeOne Medicines Ltd. | $5,582.00 | 09/23/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190340526 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,943.23 | 09/18/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184240412 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $18,838.37 | 09/12/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184236492 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,380.00 | 09/10/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES CLINICAL TRIALS OFFIC | A Modular Phase II, Single-arm, Multicenter, Open-label study to evaluate the Efficacy and Safety of AZD0486 in Subjects with Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL) | No dispute reported | 06/30/2026 | 1185554598 |
| Principal investigator 1 | BeOne Medicines Ltd. | $50,304.00 | 09/10/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190344270 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,396.00 | 09/02/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190340518 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,928.71 | 08/26/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184230635 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,210.00 | 08/12/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190327473 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 08/12/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190327475 |
| Principal investigator 1 | AstraZeneca UK Limited | $17,380.00 | 08/07/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES CLINICAL TRIALS OFFIC | phase two open label single arm trial of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma after first line acalabrutinib progression | No dispute reported | 06/30/2026 | 1185554596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,928.37 | 08/07/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184226521 |
| Principal investigator 1 | ABBVIE INC. | $4,204.00 | 08/06/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | No dispute reported | 06/30/2026 | 1202502402 |
| Principal investigator 1 | BeOne Medicines Ltd. | $47,160.00 | 07/31/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190337384 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,288.00 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222758 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $97.23 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222760 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,934.00 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222762 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $582.82 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222764 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $448.00 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222766 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17,389.48 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222768 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $18,214.00 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222770 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,782.00 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222772 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $582.82 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222774 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,927.00 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222776 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,500.00 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222778 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,900.00 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222780 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,500.00 | 07/31/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222782 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,377.00 | 07/22/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190340521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,847.80 | 07/22/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184217679 |
| Principal investigator 1 | BeOne Medicines Ltd. | $43,737.12 | 07/21/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190337359 |
| Principal investigator 1 | BeOne Medicines Ltd. | $33,536.00 | 07/21/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190344244 |
| Principal investigator 1 | BeOne Medicines Ltd. | $33,536.00 | 07/10/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190330455 |
| Principal investigator 1 | BeOne Medicines Ltd. | $33,536.00 | 07/10/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190330457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $916.99 | 07/04/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184212791 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $916.99 | 06/24/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184210606 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,226.70 | 06/23/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES CLINICAL TRIALS OFFIC | Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1185554608 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,711.86 | 06/19/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184209091 |
| Principal investigator 1 | BeOne Medicines Ltd. | $14,082.00 | 06/17/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190331071 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,437.48 | 06/12/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184206169 |
| Principal investigator 1 | BeOne Medicines Ltd. | $31,440.00 | 06/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330379 |
| Principal investigator 1 | BeOne Medicines Ltd. | $47,160.00 | 06/11/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330381 |
| Principal investigator 1 | BeOne Medicines Ltd. | $15,733.00 | 05/30/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190331073 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 05/15/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | No dispute reported | 06/30/2026 | 1202485057 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,440.40 | 05/15/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184194579 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 05/14/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323924 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $289.30 | 05/08/2025 | Non-covered Recipient Entity ATRIUM HEALTH LEVINE CANCER INSTITUTE | A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) | No dispute reported | 06/30/2026 | 1185554602 |
| Principal investigator 1 | ABBVIE INC. | $5,021.71 | 05/07/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | No dispute reported | 06/30/2026 | 1202483335 |
| Principal investigator 1 | BeiGene, Ltd. | $19,900.00 | 04/28/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190325102 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,188.03 | 04/28/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184190623 |
| Principal investigator 1 | BeiGene, Ltd. | $18,582.00 | 04/22/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321442 |
| Principal investigator 1 | BeiGene, Ltd. | $5,441.00 | 04/17/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321450 |
| Principal investigator 1 | ABBVIE INC. | $12,023.00 | 04/16/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies | No dispute reported | 06/30/2026 | 1202404234 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,667.88 | 04/15/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184183214 |
| Principal investigator 1 | BeiGene, Ltd. | $78,600.00 | 04/14/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190322236 |
| Recipient | F. Hoffmann-La Roche AG | $240.00 | 04/09/2025 | Covered Recipient Physician | Best Practices to Overcoming Challenges in Initiating Venetoclax for Patients with Chronic Lymphocytic Leukemia: Results from a United States Community-Based Healthcare Practitioner Survey | No dispute reported | 06/30/2026 | 1211538707 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,570.51 | 04/08/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184181922 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,772.50 | 03/25/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184178818 |
| Principal investigator 1 | ABBVIE INC. | $2,410.00 | 03/24/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies | No dispute reported | 06/30/2026 | 1202404219 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,771.58 | 03/11/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184170792 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 03/04/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190322148 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,757.82 | 03/04/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184156648 |
| Principal investigator 1 | BeiGene, Ltd. | $16,990.00 | 02/25/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321444 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,245.10 | 02/25/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184155638 |
| Principal investigator 1 | ABBVIE INC. | $13,067.00 | 02/14/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies | No dispute reported | 06/30/2026 | 1202404186 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,012.75 | 02/11/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184153164 |
| Principal investigator 1 | Eli Lilly and Company | $1,158.15 | 02/10/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187873685 |
| Principal investigator 1 | ABBVIE INC. | $29,880.00 | 02/06/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | No dispute reported | 06/30/2026 | 1202446779 |
| Principal investigator 1 | BeiGene, Ltd. | $47,160.00 | 02/06/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190322128 |
| Principal investigator 1 | BeiGene, Ltd. | $33,281.00 | 01/28/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321446 |
| Principal investigator 1 | AstraZeneca UK Limited | $688,353.92 | 01/27/2025 | Covered Recipient Teaching Hospital Atrium Health Cabarrus | a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma | No dispute reported | 06/30/2026 | 1185554600 |
| Principal investigator 1 | ABBVIE INC. | $10,985.00 | 01/22/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies | No dispute reported | 06/30/2026 | 1202404161 |
| Principal investigator 1 | Eli Lilly and Company | $427,159.98 | 01/22/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187871377 |
| Principal investigator 1 | BeiGene, Ltd. | $7,263.00 | 01/21/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321448 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,590.64 | 01/17/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184148053 |
| Principal investigator 1 | Eli Lilly and Company | $36,232.06 | 01/08/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | No dispute reported | 06/30/2026 | 1187872173 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,627.26 | 01/07/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184145716 |